ALK-Abelló A/S: Conjunctivitis trials

The registry lists 16 Conjunctivitis studies with ALK-Abelló A/S as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 2 7Phase 3 11Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study in Adults With Grass Pollen-induced RhinoconjunctivitisCompletedNCT04881461Phase 3Results posted
• A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)CompletedNCT01535118Results posted
• A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)CompletedNCT01385371Phase 3Results posted
• Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)CompletedNCT00978029Phase 2Results posted
• Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)CompletedNCT00783198Phase 2/3Results posted
• Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)CompletedNCT00770315Phase 2/3Results posted
• Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)CompletedNCT00562159Phase 3Results posted
• Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)CompletedNCT00550550Phase 3Results posted
• A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure ChamberTerminatedNCT04176185Phase 3
• A Trial Evaluating Tolerability of Grazax Treatment in Combination With AntihistamineCompletedNCT01740284Phase 3
• Tolerability of Grazax in Patients With Hayfever in Real Life SettingsCompletedNCT01433510Phase 4
• Comparison of Different Up-dosing Schedules With Osiris Phleum PratenseCompletedNCT01425788Phase 2
• Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic PatientsCompletedNCT00857779Phase 2
• Long-term Efficacy and Safety Study With Oralgen Grass PollenCompletedNCT00824447Phase 2/3
• A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen RhinoconjunctivitisStatus unknownNCT00812799Phase 3
• Efficacy and Safety of Grass Pollen Sublingual ImmunotherapyCompletedNCT00567346Phase 2/3